Adjuvant Therapy of T1 Bladder Carcinoma: Preliminary Results of an EORTC Randomized Study
- 1 January 1979
- book chapter
- Published by Springer Nature
- Vol. 68, 338-345
- https://doi.org/10.1007/978-3-642-81332-0_51
Abstract
Superficial bladder tumors (T1, P1 of the TNM Classification [19] or Jewett Stage O and A) are usually treated by transurethral resection (TUR). However, recurrence of the tumor after complete resection occurs in about 60% of the patients [9, 10] with a significant percentage of these recurrences showing a higher degree of malignancy [10]. In 10% of the cases the tumor progresses to invasive carcinoma [7] and the 5-year survival rate following TUR is about 62% [12].Keywords
This publication has 15 references indexed in Scilit:
- Comparisons of placebo, pyridoxine, and topical thiotepa in preventing recurrence of stage I bladder cancerUrology, 1977
- Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examplesBritish Journal of Cancer, 1977
- Benign Papilloma or Papillary Carcinoma of the Bladder?Journal of Urology, 1973
- Thiotepa Bladder Instillations: Therapy and Prophylaxis for Superficial Bladder TumorsJournal of Urology, 1969
- The Effects of Topical Thiotepa on the Recurrence Rate of Superficial Bladder CancersJournal of Urology, 1968
- The Prophylactic Use of Thio-Tepa in Transitional Cell Carcinoma of the BladderJournal of Urology, 1966
- Intracavitary Chemotherapy of Diffuse Non-Infiltrating Papillary Carcinoma of the BladderJournal of Urology, 1966
- Testing for homogeneity: II. The Poisson distributionBiometrika, 1966
- Bladder Carcinoma Treated by Direct Instillation of Thio-TepaJournal of Urology, 1962
- THIOTEPA IN THE TREATMENT OF TUMOURS OF THE BLADDERThe Lancet, 1961